Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Non Operating Income (2016 - 2025)

Ocular Therapeutix has reported Non Operating Income over the past 13 years, most recently at $5.1 million for Q4 2025.

  • Quarterly results put Non Operating Income at $5.1 million for Q4 2025, up 133.36% from a year ago — trailing twelve months through Dec 2025 was $4.1 million (up 118.77% YoY), and the annual figure for FY2025 was $4.1 million, up 118.77%.
  • Non Operating Income for Q4 2025 was $5.1 million at Ocular Therapeutix, up from -$720000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for OCUL hit a ceiling of $23.3 million in Q1 2021 and a floor of -$33.2 million in Q1 2024.
  • Median Non Operating Income over the past 5 years was $1.2 million (2022), compared with a mean of $1.8 million.
  • Biggest five-year swings in Non Operating Income: soared 975.95% in 2021 and later plummeted 327.74% in 2024.
  • Ocular Therapeutix's Non Operating Income stood at $14.2 million in 2021, then crashed by 118.62% to -$2.6 million in 2022, then surged by 162.29% to $1.6 million in 2023, then surged by 32.85% to $2.2 million in 2024, then surged by 133.36% to $5.1 million in 2025.
  • The last three reported values for Non Operating Income were $5.1 million (Q4 2025), -$720000.0 (Q3 2025), and -$173000.0 (Q2 2025) per Business Quant data.